Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

5.43
+0.43008.60%
Post-market: 5.430.00000.00%16:10 EDT
Volume:383.32K
Turnover:2.06M
Market Cap:259.27M
PE:-0.19
High:5.63
Open:5.01
Low:4.98
Close:5.00
52wk High:12.46
52wk Low:1.93
Shares:47.75M
Float Shares:32.64M
Volume Ratio:0.70
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-28.4557
EPS(LYR):-34.6700
ROE:-675.09%
ROA:-35.00%
PB:-1.22
PE(LYR):-0.16

Loading ...

Minerva Neurosciences Files Form 3 for Chief Accounting Officer Anthony Aliquo

Reuters
·
Aug 21

Minerva Neurosciences Raised to Buy from Hold by Jefferies

Dow Jones
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)

TIPRANKS
·
Aug 14

U.S. Research Roundup-Cisco, Fox Corp, Target

Reuters
·
Aug 14

Minerva Neurosciences, Inc : Jefferies Raises to Buy from Hold; Raises Target Price to $10 from $7.5

THOMSON REUTERS
·
Aug 14

Minerva Neurosciences Elevates Aliquo to Accounting Leadership

TIPRANKS
·
Aug 13

Minerva Neurosciences Names Anthony Aliquo Chief Accounting Officer

Reuters
·
Aug 13

Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate

Benzinga Earnings
·
Aug 07

Minerva Neurosciences Returns to GAAP Profit in Q2 FY26 at $17.47 Million; GAAP Net Loss Widens to $107.94 Million in H1 FY26

Reuters
·
Aug 07

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

THOMSON REUTERS
·
Aug 07

Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia

Reuters
·
Jun 05

Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting

TIPRANKS
·
Jun 05

Minerva Neurosciences shareholders approve charter amendments at annual meeting

Reuters
·
Jun 05

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

THOMSON REUTERS
·
Jun 02

Minerva Neurosciences - Topline Data From 12-Week Phase a Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 02

Minerva Neurosciences forms scientific advisory board for roluperidone program

Reuters
·
Jun 02

Minerva Neurosciences enters equity distribution deal for up to $75 million ATM offering

Reuters
·
May 28

Minerva Neurosciences - to Offer and Sell up to $75 Mln in Common Stock Through Leerink Partners - SEC Filing

THOMSON REUTERS
·
May 28

Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms

Reuters
·
May 20

Minerva Neurosciences CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 19